Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy

Clinical Studies Underway

20 Apr 2021

• By John Davis

Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.

Barcelona, Spain-based AELIX Therapeutics’s proprietary T-cell immunogen has shown a signal of therapeutic benefit in an early clinical study, and the biotech is now aiming to raise series B financing to support further development of the vaccine.

The pharmaceutical/biotech industry has a long history of disappointing attempts to successfully develop HIV prophylactic and therapeutic vaccines, but Aelix...